Abstract:
A larvicide comprising an essential oil encapsulated within a non- viable yeast cell. The larvicide is particularly effective against mosquito larvae, non-toxic to humans and other non-target species, inexpensive to make, and non-toxic during manufacture, transport, and storage.
Abstract:
Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.
Abstract:
Novel particular-based pesticides formed from pesticidal agents encapsulated in one or more coatings wherein the coating enhances the pesticidal agent' s ability to control a pest population, and methods for making the same. In various embodiments the pesticidal agent may be a biopesticide and the coating may impart stability, protection from UV radiation and/or other environmental conditions, enhance the attractiveness of the pesticide to the pest, and/or serve to separate two different biologically incompatible pesticides within a mixture.
Abstract:
Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.
Abstract:
An antibody that binds to a filovirus glycoprotein generally includes include a complementarity determining region (CDR) of any one of SEQ ID NO:27-36 or a combination of such CDRs. The antibody may be used in to detect filovirus in a biological sample obtained from a subject. The antibody also may be formulated into a pharmaceutical composition for administering to a subject having, or at risk of having, a filovirus infection.
Abstract:
An larvicide comprising an essential oil encapsulated within a non-viable yeast cell. The larvicide is particially effective against mosquito larvae, non-toxic to humans and other non-target species, inexpensive to make, and non-toxic during manufacture, transport, and storage.